BRAF V600

This case underscores the urgent need for timely recognition and intervention in giant melanoma with acute complications. It also highlights the effectiveness of modern adjuvant therapies in improving prognosis.

Despite the frequency of lymphatic metastasis, its prognostic impact varies: microscopic nodal disease has minimal effect on survival, while macroscopic or extranodal extension increases recurrence and mortality risks. This synthesis of current evidence aims to guide clinicians in optimizing detection, treatment, and surveillance for PTC patients with lymphatic metastasis.

Long-term surveillance is essential, as late recurrences can occur. In this first comprehensive review of MSO, we integrate our own case series findings with published data to provide an up-to-date synthesis of its clinicopathologic spectrum and management.

In selected fit patients, modified FOLFIRINOX may address mixed phenotypes...Research priorities include ampulla-enriched umbrella trials, explicit AC subcohorts in tissue-agnostic studies, and ctDNA-informed endpoints. This lineage-first, mutation-fast paradigm supports precision care and evidence generation in AC.

These results contrast with prior tissue-based studies and indicate that bTMB may reflect tumor burden and aggressive disease biology rather than tumor immunogenicity. Prospective studies integrating bTMB with ctDNA fraction, tumor burden metrics, and longitudinal molecular dynamics are warranted to refine its clinical utility.

The presence of CLT appears to exert a protective effect in PTC. However, the prognostic significance of BRAF V600E mutation varies with tumor size. While CLT-related inflammatory microenvironment may counteract tumor progression in small cancers, it seems insufficient to mitigate the aggressive behavior driven by BRAF V600E mutation in larger tumors.

Our findings reveal a mechanistic pathway towards enhancing radionuclide uptake in vivo, with clinical relevance for RAI therapy and identifying survival indicators of recurrent disease.

Triple therapy with encorafenib, cetuximab, and binimetinib offers meaningful improvements in survival and tumor response in BRAF V600E-mutated CRC, although the toxicity remains substantial. Optimizing patient selection and managing adverse events are critical for broader clinical use.

Preoperative NGS profiling, particularly the detection of high-risk multi-gene co-mutations, provides a powerful tool for refined risk assessment. This molecularly guided strategy has the potential to inform personalized surgical planning directly, optimizing the extent of lymph node dissection to improve oncologic outcomes while minimizing unnecessary morbidity.

Standardized molecular testing strategies will be key to enable the integration of more consistent and comparable genomic datasets across studies. Further, by elucidating the prognostic relevance of individual genomic alterations, our insights carry significant implications for interpreting single-arm clinical trials within genomically stratified patient cohorts and underscore the importance of randomized studies to delineate the benefit of targeted therapies.

P2, N=33, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2028 --> Feb 2029 | Trial primary completion date: Feb 2026 --> Feb 2029

Reflex NGS at diagnosis in resected Stage 0-IA LUAD is feasible, rapid, and reveals a high rate of actionable alterations, which may support its integration in the future into early-stage diagnostic workflows.